BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24708709)

  • 1. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.
    Li Z; Chen K; Jiang P; Zhang X; Li X; Li Z
    Diagn Pathol; 2014 Apr; 9():79. PubMed ID: 24708709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD44v6 and integrin-β1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery.
    Zhou G; Chiu D; Qin D; Niu L; Cai J; He L; Tan D; Xu K
    Diagn Pathol; 2013 Sep; 8():146. PubMed ID: 24004467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CD44 variants and its association with survival in pancreatic cancer.
    Gotoda T; Matsumura Y; Kondo H; Saitoh D; Shimada Y; Kosuge T; Kanai Y; Kakizoe T
    Jpn J Cancer Res; 1998 Oct; 89(10):1033-40. PubMed ID: 9849582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of CD44 variants expression in colorectal cancer.
    Li XD; Ji M; Wu J; Jiang JT; Wu CP
    Tumori; 2013; 99(1):88-92. PubMed ID: 23549006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study.
    Shah NG; Trivedi TI; Vora HH; Patel KC; Tankshali R; Goswami JV; Shukla SN; Shah PM
    Tumori; 2010; 96(6):971-7. PubMed ID: 21388061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
    Liu YJ; Yan PS; Li J; Jia JF
    World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component.
    Umeda T; Ishida M; Murata S; Mori T; Kawai Y; Itoi N; Tomida K; Tanaka A; Sakai S; Kitamura M; Kubota Y; Kushima R; Tani M
    Breast Cancer; 2016 Nov; 23(6):869-875. PubMed ID: 26494575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma.
    Gansauge F; Gansauge S; Rau B; Scheiblich A; Poch B; Schoenberg MH; Beger HG
    Cancer; 1997 Nov; 80(9):1733-9. PubMed ID: 9351541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms.
    Soave DF; Oliveira da Costa JP; da Silveira GG; Ianez RC; de Oliveira LR; Lourenço SV; Ribeiro-Silva A
    Diagn Pathol; 2013 Feb; 8():29. PubMed ID: 23419168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
    Joo M; Lee HK; Kang YK
    Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.
    Li L; Hao X; Qin J; Tang W; He F; Smith A; Zhang M; Simeone DM; Qiao XT; Chen ZN; Lawrence TS; Xu L
    Gastroenterology; 2014 Apr; 146(4):1108-18. PubMed ID: 24397969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis and poor prognosis in pancreatic carcinoma.
    Chen K; Li Z; Jiang P; Zhang X; Zhang Y; Jiang Y; He Y; Li X
    Oncol Rep; 2014 Aug; 32(2):755-63. PubMed ID: 24920554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.
    Miwa T; Nagata T; Kojima H; Sekine S; Okumura T
    Int J Oncol; 2017 Sep; 51(3):771-780. PubMed ID: 28677740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours.
    Imam H; Eriksson B; Oberg K
    Ann Oncol; 2000 Mar; 11(3):295-300. PubMed ID: 10811495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
    Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
    Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
    Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
    Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
    Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
    Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
    Shi J; Zhou Z; Di W; Li N
    BMC Cancer; 2013 Apr; 13():182. PubMed ID: 23565736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma.
    Zhang H; Gao H; Liu C; Kong Y; Wang C; Zhang H
    Diagn Pathol; 2015 Mar; 10():13. PubMed ID: 25890028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer.
    Dong LL; Chen LM; Wang WM; Zhang LM
    Diagn Pathol; 2015 Apr; 10():45. PubMed ID: 25924779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.